Sadly Easai turned out to be like a fool who built his house on the sand, a little wind, and our house of B toppled.....they need to choose a good partner on these new products.....
Good presentation and SP in major reverse, as our other Bios I hold. It's all HFT, HF, MM, Shorts and traders....few actually invest anymore......
Wow - didn't realize we were looking at 2018 launches. If Z rocks in EU, will FDA still want a new trial? Months of real world in EU is essentially a trial, with the real deal.
Bio....I'd take $7.33 for ARNA. Never expected it to slowly tank, nor that Easai would be a weak marketer of B. That reduced income has kept ARNA from pursuing other indications for B that would have been more marketable.
You were pumping a stock I was already in, denied, crashed to under a buck. No position in this train wreck.
Anyone think they may be looking to sell or merge? Seen that with others with a slightly failed P3.
Good news on Z in Europe could influence FDA and good news on 4 - this will easily double. My buy didn't fill today to add to position.